Ca-19-9 and CEA were measured in serum from patients with a variety of malignancies. Ca-19-9 was elevated in 97% of 30 patients with pancreatic carcinoma and 53% of 15 patients with gastric carcinomas. The main advantage of Ca-19-9 over CEA as a marker for gastrointestinal malignancy is the low number of false positive elevations in patients with benign gastrointestinal disease. It is concluded that Ca-19-9 is the best presently available biochemical marker for cancer of the pancreas.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Del Villano, B. C., Brennan, S., Brock, P.ef al. 1983. Radioimmunometric assay for a monoclonal-defined tumor marker Ca-19-9. Clin. Chem. 29, 549–552.
Koprowski, H., Herlyn, M., Steplewski, Z. and Sears, H. F. 1981. Specific antigen in serum of patients with colon cancer. Science 212, 53–55.
NIH Consensus Statement, 1981. Carcinoembryonic antigen: its role as a marker in the management of cancer. Br. Med. J. 282, 373–375.
About this article
Cite this article
Duffy, M.J., O’Sullivan, F., O’Donoghue, D. et al. Ca-19-9, A new marker for gastrointestinal malignancy. I.J.M.S. 154, 385 (1985). https://doi.org/10.1007/BF02937186
- Esophageal Cancer
- Gastric Carcinoma
- Biochemical Marker
- Pancreatic Carcinoma